Recce Pharmaceuticals Announces Positive Data on RECCE 327 Against Influenza A Respiratory Virus Infection in Animal Model

 Highlights:

• Dramatic reduction in viral load in the lungs of mice treated with RECCE 327 as compared to the approved antiviral drug treated and vehicle control untreated groups
• RECCE 327’s unique mechanism of action reinforces efficacy against both bacterial cells and enveloped viruses

SYDNEY, Australia, April 20, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE), the company developing a new class of broad-spectrum synthetic antibiotics, today announced positive efficacy data showing significant in vivo anti-viral activity against the Influenza A virus in mice treated with its lead compound RECCE 327.

Data showed a significant dose-dependent decrease in the viral growth rate and viral load in lungs of mice infected with Influenza A following treatment with RECCE 327 compared to the vehicle control group, and group treated with an approved antiviral drug ribavirin, also known as tribavirin.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c988a256-3ccb-4275 ...

Day	Vehicle control			Ribavirin 66 mg/kg i.p.			RECCE 327 500 mg/kg iv bid			RECCE 327 1000 mg/kg iv bid
	Mean	SD	N	Mean	SD	N	Mean	SD	N	Mean	SD	N
1	4.38	0.1	3	4.29	0.06	3	4.39	0.09	3	4.39	0.1	3
2	4.66	0.1	3	4.31	0.08	3	4.35	0.03	3	4.37	0.1	3
4	5.37	0	3	4.38	0.18	3	4.27	0.03	3	BLOQ	NA	3
6	5.32	NA	1	4.16	0.17	3	4.09	0.02	3	BLOQ	NA	3

NA – Not Applicable